Home
Inivata

Inivata Market Share Analysis for June 2026

neogenomics is a leader in precision oncology testing, empowering healthcare experts to optimize patient care.

Health > Biotechnology and Pharmaceuticals

Domaininivata.com

Year Founded2014

Employees51 - 200

Annual Revenue$15M - $25M

Inivata

Inivata (including company regionals)

inivata.com

See more website traffic and engagement information

Inivata Revenue up to June 2026 is 15M - 25M

revenue generated by Inivata top domains

Inivata top domains revenue over 3 years

Revenue for Inivata top domains

inivata.com15M - 25M

See more with Sales Intelligence

Total visits to Inivata's top domains

Understand Inivata market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Inivata's top domains

Analyze Inivata engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Inivata's top domains

See how Inivata keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Inivata top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Inivata

These are the website technologies, by industry, used by Inivata top domains

Widget (6)

Twemoji

Advertising (5)

DoubleClick

Marketing (3)

Google Marketing Platform

Audio Video Media (2)

YouTube

More Technologies

11

See all

News & Signals from Inivata

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsInivata launched RaDaR assay on Apr 1st '20.Inivata also introduced RaDaR assay in April 2020 to identify and track residual disease and relapse in plasma samples of patients with prior cancer diagnoses.

NewsInivata had issues with infringement of two separate patents on Dec 21st '22.Natera had first sued Inivata earlier that year for infringement of two separate patents.

NewsInivata launched data for RaDaR assay on Apr 1st '20.For instance, in June 2022, NeoGenomics’s subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.